THE IMPACT STUDY: PROPHYLAXIS WITH VALGANCICLOVIR FOR UP TO 200 DAYS POST-TRANSPLANT IN HIGH RISK KIDNEY RECIPIENTS SIGNIFICANTLY REDUCES THE INCIDENCE OF CMV DISEASE COMPARED TO 100 DAYS USE FOLLOWED BY PLACEBO
- Author
- AG Jardine, Y Lebranchu, F Vincenti, I Hauser, E Blumberg, J Punch, D Abramowicz, J Ives, Patrick Peeters (UGent) , N Pluck and A Humar
- Organization
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-989431
- MLA
- Jardine, AG, et al. “THE IMPACT STUDY: PROPHYLAXIS WITH VALGANCICLOVIR FOR UP TO 200 DAYS POST-TRANSPLANT IN HIGH RISK KIDNEY RECIPIENTS SIGNIFICANTLY REDUCES THE INCIDENCE OF CMV DISEASE COMPARED TO 100 DAYS USE FOLLOWED BY PLACEBO.” TRANSPLANT INTERNATIONAL, vol. 22, WILEY-BLACKWELL PUBLISHING, INC, 2009, pp. 93–93.
- APA
- Jardine, A., Lebranchu, Y., Vincenti, F., Hauser, I., Blumberg, E., Punch, J., … Humar, A. (2009). THE IMPACT STUDY: PROPHYLAXIS WITH VALGANCICLOVIR FOR UP TO 200 DAYS POST-TRANSPLANT IN HIGH RISK KIDNEY RECIPIENTS SIGNIFICANTLY REDUCES THE INCIDENCE OF CMV DISEASE COMPARED TO 100 DAYS USE FOLLOWED BY PLACEBO. TRANSPLANT INTERNATIONAL, 22, 93–93. MALDEN: WILEY-BLACKWELL PUBLISHING, INC.
- Chicago author-date
- Jardine, AG, Y Lebranchu, F Vincenti, I Hauser, E Blumberg, J Punch, D Abramowicz, et al. 2009. “THE IMPACT STUDY: PROPHYLAXIS WITH VALGANCICLOVIR FOR UP TO 200 DAYS POST-TRANSPLANT IN HIGH RISK KIDNEY RECIPIENTS SIGNIFICANTLY REDUCES THE INCIDENCE OF CMV DISEASE COMPARED TO 100 DAYS USE FOLLOWED BY PLACEBO.” In TRANSPLANT INTERNATIONAL, 22:93–93. MALDEN: WILEY-BLACKWELL PUBLISHING, INC.
- Chicago author-date (all authors)
- Jardine, AG, Y Lebranchu, F Vincenti, I Hauser, E Blumberg, J Punch, D Abramowicz, J Ives, Patrick Peeters, N Pluck, and A Humar. 2009. “THE IMPACT STUDY: PROPHYLAXIS WITH VALGANCICLOVIR FOR UP TO 200 DAYS POST-TRANSPLANT IN HIGH RISK KIDNEY RECIPIENTS SIGNIFICANTLY REDUCES THE INCIDENCE OF CMV DISEASE COMPARED TO 100 DAYS USE FOLLOWED BY PLACEBO.” In TRANSPLANT INTERNATIONAL, 22:93–93. MALDEN: WILEY-BLACKWELL PUBLISHING, INC.
- Vancouver
- 1.Jardine A, Lebranchu Y, Vincenti F, Hauser I, Blumberg E, Punch J, et al. THE IMPACT STUDY: PROPHYLAXIS WITH VALGANCICLOVIR FOR UP TO 200 DAYS POST-TRANSPLANT IN HIGH RISK KIDNEY RECIPIENTS SIGNIFICANTLY REDUCES THE INCIDENCE OF CMV DISEASE COMPARED TO 100 DAYS USE FOLLOWED BY PLACEBO. In: TRANSPLANT INTERNATIONAL. MALDEN: WILEY-BLACKWELL PUBLISHING, INC; 2009. p. 93–93.
- IEEE
- [1]A. Jardine et al., “THE IMPACT STUDY: PROPHYLAXIS WITH VALGANCICLOVIR FOR UP TO 200 DAYS POST-TRANSPLANT IN HIGH RISK KIDNEY RECIPIENTS SIGNIFICANTLY REDUCES THE INCIDENCE OF CMV DISEASE COMPARED TO 100 DAYS USE FOLLOWED BY PLACEBO,” in TRANSPLANT INTERNATIONAL, 2009, vol. 22, pp. 93–93.
@inproceedings{989431,
author = {{Jardine, AG and Lebranchu, Y and Vincenti, F and Hauser, I and Blumberg, E and Punch, J and Abramowicz, D and Ives, J and Peeters, Patrick and Pluck, N and Humar, A}},
booktitle = {{TRANSPLANT INTERNATIONAL}},
issn = {{0934-0874}},
language = {{eng}},
pages = {{93--93}},
publisher = {{WILEY-BLACKWELL PUBLISHING, INC}},
title = {{THE IMPACT STUDY: PROPHYLAXIS WITH VALGANCICLOVIR FOR UP TO 200 DAYS POST-TRANSPLANT IN HIGH RISK KIDNEY RECIPIENTS SIGNIFICANTLY REDUCES THE INCIDENCE OF CMV DISEASE COMPARED TO 100 DAYS USE FOLLOWED BY PLACEBO}},
volume = {{22}},
year = {{2009}},
}